A.P. Nizovtsev

Dr. A.P. Nizovtsev is a Doctor of Science in Physics and Mathematics working as a Researcher at the National Academy of Sciences of Belarus, Department of Physics, Mathematics and Informatics. He has been a leading researcher at the Laboratory of quantum optics since September 2013 and is associated with CQOQI (Sergei Ya Kilin's Lab). With 157 publications, 15,159 reads, and 1,493 citations, Dr. Nizovtsev has established a significant research profile in quantum physics and computational nanomedicine.

His research spans two primary domains:

• Quantum Physics and Quantum Technologies: Focusing on nitrogen-vacancy (NV) centers in diamond for quantum information processing, quantum sensing, and magnetic field detection applications.
• Quantum Chemistry and Nanomedicine: Specializing in computational modeling of fullerenol-based conjugates for cancer therapy applications, particularly studying drug delivery systems involving carboplatin, cisplatin, and other therapeutic agents.

Dr. Nizovtsev employs advanced computational methods including HF-3c, DFT, and ORCA software packages to model complex molecular systems and quantum phenomena. His recent publications (2024-2025) demonstrate continued productivity with multiple papers on three-component systems for cancer therapy and advanced quantum sensing techniques using diamond NV centers.

His professional network includes collaborations with researchers across multiple institutions, indicating active participation in the international scientific community. The substantial citation count of his work reflects the impact and recognition of his contributions to quantum physics and computational nanomedicine, particularly in bridging fundamental quantum phenomena with potential biomedical applications.

As a leading researcher at the Laboratory of quantum optics, Dr. Nizovtsev contributes to advancing quantum technologies and their applications, particularly in the areas of quantum memory, quantum sensing, and the development of novel nanomedicine approaches for cancer treatment through improved drug delivery systems.